Idiopathische inflammatorische Myopathien

Abstract

Myositis is a rare and an extremely heterogeneous autoimmune disease, that causes muscle weakness. Currently, “idiopathic inflammatory myopathies (IIM)“ is the preferred umbrella-term used to describe the disease complexity within individuals. IIM include dermatomyositis, polymyositis, inclusion body myositis, autoimmune necrotizing myopathy, overlap myositis and antisynthetase syndrome. Research activity concerning myositis was very intense over the past ten years and led to new diagnostic approach as well as to novel therapeutic strategies. Correct classification is the key for successful management. One single treatment regime for every possible organ involvement in all different forms of IIM is still not existing.

Idiopathische inflammatorische Myopathien sind seltene heterogene Autoimmunerkrankungen, die mit einer Muskelschwäche einhergehen. Kommen zur Muskelschwäche Haut- oder Allgemeinsymptome wie Fatigue und Fieber hinzu oder andere Auffälligkeiten, sollten Behandelnde aufmerksam werden. Dieser Beitrag stellt die wesentlichen Erkenntnisse zu Diagnose und Therapie der Erkrankung mit ihren komplexen unterschiedlichen Unterformen vor.

Schlüsselwörter

Myositis - Dermatomyositis - Antisynthetase-Syndrom - idiopathische inflammatorische Myopathien

Key words

myositis - dermatomyositis - antisynthetase syndrome - idiopathic inflammatory myopathies

Publication History

Article published online:
02 July 2020

• Literatur

• 1 Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015; 372: 1734-1747 . doi:10.1056/NEJMra1402225
• 2 Meyer A, Meyer N, Schaeffer M. et al Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford) 2015; 54: 50-63 . doi:10.1093/rheumatology/keu289
• 3 Lilleker JB, Vencovsky J, Wang G. et al The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis 2018; 77: 30-39 . doi:10.1136/annrheumdis-2017-211868
• 4 Fredi M, Cavazzana I, Franceschini F. The clinico-serological spectrum of overlap myositis. Curr Opin Rheumatol 2018; 30: 637-643 . doi:10.1097/bor.0000000000000536
• 5 Cavagna L, Nuno L, Scire CA. et al Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. Clin Rev Allergy Immunol 2017; 52: 71-80 . doi:10.1007/s12016-016-8528-9
• 6 Chen Z, Wang X, Ye S. Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. N Engl J Med 2019; 381: 291-293 . doi:10.1056/NEJMc1900045
• 7 Baschung Pfister P, de Bruin ED, Sterkele I. et al Manual muscle testing and hand-held dynamometry in people with inflammatory myopathy: An intra- and interrater reliability and validity study. PLoS One 2018; 13: e0194531 . doi:10.1371/journal.pone.0194531
• 8 Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-982 . doi:10.1016/s0140-6736(03)14368-1
• 9 Monti S, Montecucco C, Cavagna L. Clinical spectrum of anti-Jo-1-associated disease. Curr Opin Rheumatol 2017; 29: 612-617 . doi:10.1097/bor.0000000000000434
• 10 Isenberg DA, Allen E, Farewell V. et al International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004; 43: 49-54 . doi:10.1093/rheumatology/keg427
• 11 Stuhlmuller B, Schneider U, Gonzalez-Gonzalez JB. et al Disease Specific Autoantibodies in Idiopathic Inflammatory Myopathies. Front Neurol 2019; 10: 438 . doi:10.3389/fneur.2019.00438
• 12 Leatham H, Schadt C, Chisolm S. et al Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts. Medicine (Baltimore) 2018; 97: e9639 . doi:10.1097/md.0000000000009639
• 13 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-347 . doi:10.1056/nejm197502132920706
• 14 Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-407 . doi:10.1056/nejm197502202920807
• 15 Michelle EH, Mammen AL. Myositis Mimics. Curr Rheumatol Rep 2015; 17: 63 . doi:10.1007/s11926-015-0541-0
• 16 Lundberg IE, Tjarnlund A, Bottai M. et al 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol 2017; 69: 2271-2282 . doi:10.1002/art.40320
• 17 Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev Rheumatol 2018; 14: 279-289 . doi:10.1038/nrrheum.2018.42
• 18 Fasano S, Gordon P, Hajji R. et al Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford) 2017; 56: 26-36 . doi:10.1093/rheumatology/kew146
• 19 Hornig J, Weinhage T, Schmidt LH. et al. Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment. Z Rheumatol 2018; DOI: 10.1007/s00393-018-0565-8.
• 20 Alexanderson H, Munters LA, Dastmalchi M. et al Resistive home exercise in patients with recent-onset polymyositis and dermatomyositis -- a randomized controlled single-blinded study with a 2-year followup. J Rheumatol 2014; 41: 1124-1132 . doi:10.3899/jrheum.131145